Last reviewed · How we verify
NCT07179536: OPTIMA
Time to Ambulation After ProGlide Closure
NA trial testing Ambulation after ProGlide Closure in Femoral Access Site Closure in 300 participants. Currently enrolling.
30 March 2026
Quick facts
| Lead sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 300 |
| Start date | 1 October 2025 |
| Primary completion | 30 March 2026 |
| Estimated completion | 30 March 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Ambulation after ProGlide Closure
Conditions studied
- Femoral Access Site Closure — all drugs for Femoral Access Site Closure →
- Ambulation — all drugs for Ambulation →
- Vascular Access Complication — all drugs for Vascular Access Complication →
- Vascular Access Site Management — all drugs for Vascular Access Site Management →
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital
Who can join
Adults 18 to 75, any sex, with Femoral Access Site Closure or Ambulation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Transradial access has become the standard for coronary procedures due to fewer vascular complications and shorter bed rest, yet transfemoral access remains essential for complex peripheral interventions requiring larger sheaths and stronger support. Vascular closure devices (VCDs), particularly suture-mediated devices such as ProGlide, have improved femoral access by reducing hemostasis time, ambulation delay, and patient discomfort. Although early ambulation after ProGlide closure has been reported, current practice varies widely, and the relationship between ambulation timing and vascular complications remains unclear. This trial aims to evaluate the effect of different ambulation times after ProGlide closure in transfemoral peripheral angiography or intervention, with the goal of identifying the optimal time to ambulation that balances safety and efficiency.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07179536
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Chinese Academy of Medical Sciences, Fuwai Hospital trials
Trials by the same sponsor.
- NCT07450196 — A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Val · not yet recruiting
- NCT07511309 — FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial · NA · not yet recruiting
- NCT07054541 — A Novel Echocardiography-Guided Strategy for Percutateous Closure of Atrial Septal Defect Assisted by PannaWire · Phase 4 · not yet recruiting
- NCT07458672 — TAVR for Aortic Regurgitation Under TTE Guidance · NA · not yet recruiting
- NCT07462325 — Proteomic and Inflammatory Omics Changes With Colchicine Therapy in Coronary Heart Disease · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07179536 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences, Fuwai Hospital
- Last refreshed: 23 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07179536.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing